Septerna, Inc.'s Lock-Up Period Will End on April 23rd (NASDAQ:SEPN)

Septerna's (NASDAQ:SEPN - Get Free Report) lock-up period will expire on Wednesday, April 23rd. Septerna had issued 16,000,000 shares in its initial public offering on October 25th. The total size of the offering was $288,000,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SEPN. Wells Fargo & Company cut their price objective on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, March 28th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th.

Septerna Stock Down 1.5 %

Shares of NASDAQ SEPN traded down $0.09 during midday trading on Friday, hitting $5.90. The company had a trading volume of 211,957 shares, compared to its average volume of 439,031. The firm has a 50-day simple moving average of $6.56. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.13 million. Equities research analysts expect that Septerna will post -7.11 EPS for the current fiscal year.

Insider Activity

In other Septerna news, CFO Gil M. Labrucherie bought 5,000 shares of Septerna stock in a transaction that occurred on Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the transaction, the chief financial officer now owns 30,000 shares of the company's stock, valued at $175,500. This represents a 20.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan Ezekowitz bought 41,355 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The stock was bought at an average cost of $6.00 per share, for a total transaction of $248,130.00. Following the completion of the transaction, the director now directly owns 104,101 shares of the company's stock, valued at approximately $624,606. The trade was a 65.91 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 74,346 shares of company stock worth $439,670 over the last three months.

Institutional Investors Weigh In On Septerna

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in shares of Septerna in the fourth quarter worth $160,205,000. TRV GP V LLC acquired a new position in Septerna during the 4th quarter worth $142,337,000. TRV GP VI LLC bought a new stake in shares of Septerna in the 4th quarter worth about $72,191,000. Samsara BioCapital LLC bought a new position in shares of Septerna during the fourth quarter worth about $63,399,000. Finally, Driehaus Capital Management LLC acquired a new position in Septerna in the fourth quarter worth about $59,301,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.